Based on this study, the dose of ASP8273 300 mg daily was selected for a recently initiated, large (n = 600), international, randomized, phase III study (SOLAR) to compare the clinical efficacy and safety/tolerability of ASP8273 with erlotinib or gefitinib as initial treatment of advanced EGFR-mutant NSCLC (NCT02588261). Here, EGFR is linked to non-small cell lung carcinoma.